SHAREHOLDERS' EQUITY	9 Months Ended
Sep. 30, 2023
Equity [Abstract]
SHAREHOLDERS' EQUITY	14. SHAREHOLDERS’ EQUITY: Preferred Stock The Company’s Amended and Restated Articles of Incorporation authorize it to issue up to 5,000,000 shares of $0.01 par value preferred stock with designations, rights and preferences determined from time-to-time by the Company’s Board of Directors. Accordingly, the Company’s Board of Directors is empowered, without shareholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of shareholders of the Company’s common stock. In 1995, the Company issued 200,000 shares of Series A Nonconvertible Preferred Stock (Series A) to American Biomimetics Corporation (ABC) pursuant to a certain Technology Transfer Agreement between the Company and ABC. The Series A shares have a liquidation value of $7.50 per share. Series A shareholders, as a single class, have the right to elect two members of the Company’s Board of Directors. This right has never been exercised. Holders of the Series A shares are entitled to one vote per share on matters which shareholders are generally entitled to vote. The Series A shareholders are not entitled to any dividends. As of September 30, 2023, the Company had issued 200,000 shares of preferred stock, all of which were outstanding. Common Stock The Company’s Amended and Restated Articles of Incorporation authorize it to issue up to 200,000,000 shares of $0.01 par value common stock. Each share of the Company’s common stock entitles the holder to one vote on all matters to be voted upon by the shareholders. As of September 30, 2023, the Company had issued 48,720,530 shares of common stock, of which 47,354,882 were outstanding. During the three and nine months ended September 30, 2023 and 2022, the Company repurchased no shares of common stock. Dividends During the three months ended September 30, 2023, the Company declared and paid cash dividends of $0.35 per common share, or $16.7 million, and during the nine months ended September 30, 2023, the Company declared and paid cash dividends of $1.05 per common share, or $50.1 million, on the Company’s outstanding common stock. On October 31, 2023, the Company’s Board of Directors declared a fourth quarter dividend of $0.35 per share to be paid on December 29, 2023 to all shareholders of record of the Company’s common stock as of the close of business on December 15, 2023. All future dividends will be subject to the approval of the Company’s Board of Directors.

SHAREHOLDERS' EQUITY

9 Months Ended

Sep. 30, 2023

14. SHAREHOLDERS’ EQUITY:

Preferred Stock

The Company’s Amended and Restated Articles of Incorporation authorize it to issue up to 5,000,000 shares of $0.01 par value preferred stock with designations, rights and preferences determined from time-to-time by the Company’s Board of Directors. Accordingly, the Company’s Board of Directors is empowered, without shareholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of shareholders of the Company’s common stock.

In 1995, the Company issued 200,000 shares of Series A Nonconvertible Preferred Stock (Series A) to American Biomimetics Corporation (ABC) pursuant to a certain Technology Transfer Agreement between the Company and ABC. The Series A shares have a liquidation value of $7.50 per share. Series A shareholders, as a single class, have the right to elect two members of the Company’s Board of Directors. This right has never been exercised. Holders of the Series A shares are entitled to one vote per share on matters which shareholders are generally entitled to vote. The Series A shareholders are not entitled to any dividends.

As of September 30, 2023, the Company had issued 200,000 shares of preferred stock, all of which were outstanding.

Common Stock

The Company’s Amended and Restated Articles of Incorporation authorize it to issue up to 200,000,000 shares of $0.01 par value common stock. Each share of the Company’s common stock entitles the holder to one vote on all matters to be voted upon by the shareholders.

As of September 30, 2023, the Company had issued 48,720,530 shares of common stock, of which 47,354,882 were outstanding. During the three and nine months ended September 30, 2023 and 2022, the Company repurchased no shares of common stock.

Dividends

During the three months ended September 30, 2023, the Company declared and paid cash dividends of $0.35 per common share, or $16.7 million, and during the nine months ended September 30, 2023, the Company declared and paid cash dividends of $1.05 per common share, or $50.1 million, on the Company’s outstanding common stock.

On October 31, 2023, the Company’s Board of Directors declared a fourth quarter dividend of $0.35 per share to be paid on December 29, 2023 to all shareholders of record of the Company’s common stock as of the close of business on December 15, 2023. All future dividends will be subject to the approval of the Company’s Board of Directors.